Last reviewed · How we verify

NCT04510727

Optical Coherence Tomography Guided C&D

Withdrawn NA Last updated 20 February 2024
What this trial tests

NA trial testing Optical Coherence Tomography (OCT) in Basal Cell Carcinoma. Withdrawn.

Timeline
1 April 2024
Primary endpoint
1 February 2025
1 February 2025

Quick facts

Lead sponsorUniversity of Miami
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Start date1 April 2024
Primary completion1 February 2025
Estimated completion1 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Miami

Who can join

18 and older, any sex, with Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to identify the presence of residual superficial and nodular basal cell carcinoma (BCC) status-post curettage and desiccation (C\&D) by using optical coherence tomography (OCT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Optical Coherence Tomography (OCT)

Trials testing the same drug.

Other recruiting trials for Basal Cell Carcinoma

Currently open trials in the same condition.

Other University of Miami trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04510727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing